Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive glucose control combined with dual RAS inhibition in type 2 diabetic nephropathy
ChiCTR1900024752Phase 4Recruiting
- Sponsor
- Army Medical University
- Start
- Aug 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of valsartan, perindopril and human insulin in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Army Medical University. Primary endpoint: Urinary albumin-to-creatinine ratio at 48 weeks. Started Aug 2019; status: recruiting.
02
Drugs
valsartanperindoprilhuman insulin
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1900024752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024752.